Spectral Medical Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Spectral Medical wird voraussichtlich einen Umsatzanstieg von 24.4% pro Jahr verzeichnen. Der Gewinn pro Aktie wird voraussichtlich wachsen.

Wichtige Informationen

n/a

Wachstumsrate der Gewinne

48.9%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	41.4%
Wachstumsrate der Einnahmen	21.3%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	12 Aug 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

We're Keeping An Eye On Spectral Medical's (TSE:EDT) Cash Burn Rate

Feb 12

Gewinn- und Umsatzwachstumsprognosen

TSX:EDT - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (CAD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2025	2	N/A	N/A	N/A	1
12/31/2024	2	N/A	N/A	N/A	1
6/30/2024	2	-19	-9	-9	N/A
3/31/2024	2	-19	-9	-8	N/A
12/31/2023	2	-16	-11	-11	N/A
9/30/2023	2	-10	-11	-11	N/A
6/30/2023	2	-9	-10	-10	N/A
3/31/2023	2	-7	-11	-11	N/A
12/31/2022	2	-8	-10	-10	N/A
9/30/2022	2	-7	-10	-10	N/A
6/30/2022	1	-7	-10	-10	N/A
3/31/2022	2	-7	-10	-9	N/A
12/31/2021	2	-7	-9	-9	N/A
9/30/2021	2	-8	-9	-8	N/A
6/30/2021	2	-8	-9	-8	N/A
3/31/2021	2	-7	-8	-7	N/A
12/31/2020	2	-9	-1	0	N/A
9/30/2020	2	-8	-1	0	N/A
6/30/2020	2	-8	1	1	N/A
3/31/2020	3	-7	2	2	N/A
12/31/2019	3	-5	-3	-3	N/A
9/30/2019	4	-3	-2	-2	N/A
6/30/2019	4	-2	-2	-1	N/A
3/31/2019	3	-3	-2	-2	N/A
12/31/2018	4	-2	-2	-2	N/A
9/30/2018	3	-4	-3	-3	N/A
6/30/2018	3	-4	-3	-3	N/A
3/31/2018	4	-4	N/A	-3	N/A
12/31/2017	4	-4	N/A	-4	N/A
9/30/2017	4	-4	N/A	-5	N/A
6/30/2017	4	-6	N/A	-7	N/A
3/31/2017	3	-8	N/A	-9	N/A
12/31/2016	4	-10	N/A	-11	N/A
9/30/2016	3	-11	N/A	-11	N/A
6/30/2016	3	-11	N/A	-10	N/A
3/31/2016	3	-10	N/A	-9	N/A
12/31/2015	3	-10	N/A	-9	N/A
9/30/2015	3	-10	N/A	-9	N/A
6/30/2015	3	-9	N/A	-9	N/A
3/31/2015	3	-9	N/A	-9	N/A
12/31/2014	3	-9	N/A	-10	N/A
9/30/2014	3	-11	N/A	-11	N/A
6/30/2014	3	-12	N/A	-10	N/A
3/31/2014	3	-12	N/A	-10	N/A
12/31/2013	3	-11	N/A	-9	N/A
9/30/2013	3	-10	N/A	-8	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: Unzureichende Daten, um festzustellen, ob das prognostizierte Gewinnwachstum von EDT über der Sparquote liegt (2.1%).

Ertrag vs. Markt: Unzureichende Daten, um festzustellen, ob die Gewinne von EDT schneller wachsen werden als der Markt Canadian

Hohe Wachstumserträge: Die Daten reichen nicht aus, um festzustellen, ob die Einnahmen von EDT in den nächsten 3 Jahren erheblich steigen werden.

Einnahmen vs. Markt: EDTDie Einnahmen des Unternehmens (24.4% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Canadian (7.3% pro Jahr).

Hohe Wachstumseinnahmen: EDTDie Einnahmen des Unternehmens (24.4% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von EDT in 3 Jahren voraussichtlich hoch sein wird

Spectral Medical Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target increased by 13% to CA$1.80

Consensus revenue estimates increase by 186%

Consensus revenue estimates decrease by 61%, EPS upgraded

No longer forecast to breakeven

Consensus forecasts updated

Consensus forecasts updated

Recent updates

Independent Chairman of the Board recently sold CA$98k worth of stock

Spectral Medical Inc. Provides August Tigris Trial Update

Second quarter 2024 earnings released: CA$0.016 loss per share (vs CA$0.014 loss in 2Q 2023)

Spectral Medical Inc Provides July Tigris Trial Update

Spectral Medical Inc. announced that it has received $1 million in funding

Spectral Medical Inc. announced that it expects to receive $1 million in funding

Spectral Medical Inc. Provides June Tigris Trial Update

Independent Chairman of the Board exercised options to buy CA$102k worth of stock.

Spectral Medical Inc. announced that it has received CAD 8.499564 million in funding

First quarter 2024 earnings released: CA$0.015 loss per share (vs CA$0.006 loss in 1Q 2023)

Spectral Medical Inc. announced that it expects to receive CAD 8.499564 million in funding

Spectral Medical Inc. Provides Tigris Trial Update

Spectral Medical Provides Tigris Trial Update

Less than half of directors are independent

Price target increased by 13% to CA$1.80

Spectral Medical Inc. Announces Board Changes

Full year 2023 earnings: EPS and revenues miss analyst expectations

Spectral Medical Inc., Annual General Meeting, Jun 07, 2024

New minor risk - Market cap size

Spectral Medical Inc. Provides Update on the Company's Tigris Trial

Spectral Medical Announces Major Milestone by Reaching Its Interim Enrollment Target of 90 Patients

Spectral Medical Inc. Provides Early February Tigris Trial Update

Spectral Medical Provides January Tigris Trial Update

Spectral Medical Inc. l Enrolls Patient 82 in Its Phase 3 FDA Tigris Septic Shock Trial

Spectral Medical Inc. Provides November Tigris Trial Update

Spectral Medical Inc. Announces Executive Changes

Spectral Medical Inc. Announces Executive Changes

Spectral Medical Inc. Announces Publication of Tigris Trial Methods Paper

Third quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

Spectral Medical Provides Tigris Trial Update

New minor risk - Shareholder dilution

Spectral Medical Inc. announced that it has received CAD 6.217075 million in funding

Spectral Medical Inc. announced that it expects to receive CAD 5 million in funding from Paradigm Capital Inc.

Second quarter 2023 earnings released: CA$0.014 loss per share (vs CA$0.011 loss in 2Q 2022)

Spectral Medical Inc. Announces Tigris Clinical Trial Update

Spectral Medical Inc. Appoints David W. Feigal to Its Board of Directors

Spectral Medical Inc. Provides Update on Continued Favorable Tigris Clinical Trial Enrollment

Spectral Medical Inc. Provides Update on Favorable Tigris Clinical Trial Enrollment

Consensus revenue estimates increase by 186%

Consensus revenue estimates decrease by 61%, EPS upgraded

First quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

Spectral Medical Inc. Announces Resignation of Jim Funk as Director

No longer forecast to breakeven

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Spectral Medical Inc. Provides Update on Tigris Clinical Trial

Consensus forecasts updated

Consensus forecasts updated

Price target decreased to CA$2.10

Forecast to breakeven in 2024

Spectral Medical Inc. announced that it has received CAD 6.8364 million in funding

Spectral Medical Inc. announced that it expects to receive CAD 8.5 million in funding

Spectral Medical Inc. announced that it expects to receive CAD 8.5 million in funding

Consensus forecasts updated

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Spectral Medical Provides Update on Tigris Clinical Trial

US FDA Grants Spectral Medical Breakthrough Device Designation for Toraymyxin™ for the Treatment of Endotoxemic Septic Shock

Spectral Medical Inc. Elects James Funk as Director

Spectral Medical Inc. Appoints Sam Amory as Dialco, President

First quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Price target decreased to CA$2.10

Forecast breakeven date pushed back to 2024

Consensus revenue estimates fall by 44%

Spectral Medical Inc., Annual General Meeting, Jun 09, 2022

Spectral Medical Inc. Through Its Wholly-Owned Subsidiary Dialco Medical Inc. Provides Clinical Trial Update on Tigris, A Follow on Study Designed to Build on Knowledge Gained from the Earlier Euphrates Trial

We're Keeping An Eye On Spectral Medical's (TSE:EDT) Cash Burn Rate

Forecast to breakeven in 2023

Third quarter 2021 earnings released: CA$0.008 loss per share (vs CA$0.007 loss in 3Q 2020)

Price target decreased to CA$2.85

Independent Chairman of the Board recently bought CA$180k worth of stock